PURCHASE, N.Y.--(BUSINESS WIRE)--Nutrition 21, Inc. (NASDAQ: NXXI) today announced new published results from a 447 subject, randomized, double-blind, placebo-controlled clinical study that showed Diachrome®, a patented combination of chromium picolinate and biotin, significantly improved glycemic control in patients with poorly controlled blood sugar levels who were being treated with oral anti-diabetic medication (OADs). Patients in the treatment group showed significant improvements in glycemic control (A1C) compared with placebo (an absolute decrease of 0.54%). The greatest improvement was seen in those patients with the poorest glycemic control (baseline A1C levels equal to or greater than 10%). These patients saw an additional absolute A1C decrease of 1.76% despite the fact that they were taking one or more OAD medications.
